Antares Pharma, Inc. (Antares) is a specialized pharma product development and pipeline company with drug delivery platforms, including Advanced Transdermal Delivery (ATD) gels, oral (Easy Tec) tablets, disposable pressure assisted auto injection systems (Vibex), reusable needle-free injection systems (VISION and Valeo) and disposable pen injection systems. Two of these platforms have generated United States Food and Drug Administration (FDA) approved products. The Company has operating facilities in the United States and Switzerland. Its United States operation manufactures and markets reusable needle-free injection devices and related disposables, and develops disposable pressure assisted auto injector and pen injector systems. It also has operations located in Basel, Switzerland, which consist of administration and facilities for the development of transdermal gels and oral disintegrating tablet products. (Source: 10-K)
http://www.mivtherapeutics.com
MIV Therapeutics Inc. (MIVT) is an advanced stage, research and development company pursuing the commercialization of the next-generation biocompatible coatings for stents and other medical devices, and advanced drug delivery systems with the intent of providing healing solutions for cardiovascular disease and other medical conditions. In collaboration with the University of British Columbia (UBC), the Company has developed coating technologies that utilize Hydroxyapatite (HAp) for application on medical devices and drug delivery systems. Simultaneously, alternative polymer-free coatings and advanced polymeric coatings with enhanced biocompatibility and bioavailability were developed at its wholly owned subsidiary, MIVI Technologies Inc. (Source: 10-K)
Eurand N.V. is a specialty pharmaceutical company that develops, manufactures and commercializes pharmaceutical and biopharmaceutical products based on its drug formulation technologies. The Company has applied its technologies to drug products in a range of therapeutic areas, including cardiovascular, gastrointestinal, pain, nutrition and respiratory. In December 2007, it completed the rolling submission of a new drug application (NDA) for its lead product candidate, Zentase (formerly known as EUR-1008), which is being evaluated for the treatment of exocrine pancreatic insufficiency (EPI). The NDA was accepted for filing and granted priority review in February 2008. In addition to Zentase the Company is also developing a number of other products both for its collaboration partners and its portfolio. As of December 2007, the most advanced of its pipeline products include two co-development products and one product candidate. (Source: 20-F)
InSite Vision Incorporated is an ophthalmic product development company focused on ophthalmic pharmaceutical products based on its DuraSite drug delivery technology. Its DuraSite sustained delivery technology is a synthetic polymer-based formulation designed to extend the residence time of a drug relative to conventional topical therapies. It enables topical delivery of a solution, gel or suspension and can be customized for delivering a variety of potential drug candidates. It focused its research and development and commercial efforts on topical anti-infective products that formulate the antibiotic azithromycin with its DuraSite drug delivery technology. Its primary products include AzaSite for Bacterial Conjunctivitis (pink eye); AzaSite Plus (ISV-502), which is in Phase III Trials for Blepharoconjunctivitis; AzaSite Otic (ISV-016) a pre-clinical development for ear infections, and AzaSite Xtra (ISV-405) a pre-clinical development for Ocular Infections in International Markets. (Source: 10-K)
Biovail Corporation (Biovail) is a specialty pharmaceutical company that applies advanced drug-delivery technologies to improve the clinical effectiveness of medicines. The Company is engaged in the formulation, clinical testing, registration, manufacture and commercialization of pharmaceutical products. Its main therapeutic areas of focus are central nervous system (CNS) disorders, pain management and cardiovascular disease. The primary markets for its products are the United States and Canada. Biovail has a portfolio of drug-delivery technologies includes controlled release, enhanced absorption, rapid absorption, taste masking, and oral disintegration technologies, among others. In September 2008, Biovail acquired Prestwick Pharmaceuticals, Inc., a company that holds the Canadian and United States rights to Xenazine (tetrabenazine tablets).
Bioject Medical Technologies Inc. develops needle-free injection systems for injectable medications and vaccines. The Company’s long-term goal is to become a supplier of needle-free injection systems to the pharmaceutical and biotechnology industries. In 2007, Bioject Medical Technologies focused its business development efforts on new and existing licensing and supply agreements with pharmaceutical and biotechnology companies. Its pipeline of prospective partnerships remains active. (Source: 10-K)
Hospira, Inc. (Hospira) is a specialty pharmaceutical and medication delivery company. Hospira is engaged in the development, manufacture and marketing of specialty injectable pharmaceuticals and medication delivery systems that deliver drugs and intravenous (I.V.) fluids. Hospira is also a provider of contract manufacturing services to pharmaceutical and biotechnology companies for formulation development, filling and finishing of injectable pharmaceuticals. Hospira’s portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. During the year ended December 31, 2007, the Company’s sales in United States accounted for approximately 69% and sales outside the United States accounted for the remaining 31% of its total sales. In October 2008, the Company acquired EndoTool business from MD Scientific, LLC.
Elan Corporation, plc (Elan) is a neuroscience-based biotechnology company. Its operations are organized into two business units: Biopharmaceuticals and Elan Drug Technologies (EDT). Biopharmaceuticals engages in research, development and commercial activities primarily areas, such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis (MS), Crohn’s disease (CD) and severe chronic pain. EDT is a specialty pharmaceutical business unit of Elan. Elan’s marketed products in the the United States include PRIALT (ziconotide intrathecal infusion), AZACTAM (aztreonam for injection, USP) and MAXIPIME (cefepime hydrochloride) for Injection. On June 5, 2006, Elan and Biogen Idec announced the approval of a supplemental Biologics License Application (sBLA) by the United States Food and Drug Administration for the reintroduction of TYSABRI (natalizumab) as a monotherapy treatment for relapsing forms of MS to slow the progression of disability and reduce the frequency of clinical relapses.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory